Bryan, Garnier & Co acts as Sole Financial Advisor to the shareholders of Nehs Digital and Xperis on their sale to Enovacom
Both present in 600 healthcare institutions, 900 social healthcare establishments, and more than 800 radiology practices in France, NEHS Digital and Xperis cover five key areas of expertise: medical imaging, telemedicine, the organization of medical interpretation services, the production and coordination of care, and the security and interoperability of information systems.
With the integration of NEHS Digital and Xperis, Enovacom’s team will benefit from the expertise of both companies’ 600 e-health professionals. Already recognised for its expertise in the healthcare data interoperability sector, the acquisition of Xperis completes Enovacom’s range of solutions.
By acquiring Nehs Digital, Enovacom re-affirms its strong positioning in the telemedicine space and will complement its existing solutions, such as Enovacom Nomadeec. As a result of these acquisitions, Enovacom is now set to become a leading player in digital medical imagery, both as an integrator and a service provider.
Bryan, Garnier & Co acted as Sole Financial Advisor to the shareholders of Nehs Digital, a service provider and distributor of healthcare solutions, and Xperis, a healthcare data interoperability specialist, on their sale to Enovacom, a subsidiary of Orange Business.
Limited auctions involving Tier-1 trade buyers were conducted by Bryan, Garnier & Co.
This marks another landmark transaction for Bryan, Garnier & Co’s Software & Fintech practice. Other recent transactions include the sale of Sinari to Bridgepoint Development Capital, the disposal of Nomadia to Hg Capital and Carlyle’s investment in Groupe Lacour.
Following on from Median Technologies, Evolucare, Padoa, Arche MC2, CBA, Maincare Solutions, BlueBee, Amplexor Life Sciences, Qare, and numerous other landmark transactions in the healthcare technologies sector, this new deal marks another milestone for Bryan, Garnier & Co’s expertise.
"Bryan Garnier’s team played a pivotal role in structuring an optimal financing solution for Abivax. This is our 5th operation with Bryan Garnier, and their ability to bring together multiple stakeholders to negotiate complex agreements and provide tailored financing has proven to be invaluable. We’ve come to understand just how critical it is to have advisors who know our objectives and clinical development goals, and look forward to continuing our successful partnership."
— Didier Blondel - CFO, Abivax